Michael Pehl joined ADCendo as Chief Executive Officer in June 2021. Michael has over 25 years of international biotechnology and oncology leadership experience in both the US and Europe. He joins ADCendo from GEMoaB, where he served as CEO and led the recent formation and launch of a globally leading allogeneic CAR-T company together with Blackstone Life Sciences and Intellia Therapeutics. Prior to this, he was CEO of Immunomedics Inc. and before that President of Hematology & Oncology at Celgene Corporation in New Jersey, U.S.A.
Michael has led the global development and commercialization of multiple successful blockbuster products across both oncology and hematology, including Lenalidomide (Revlimid®), Pomalidomide (Pomalyst®; Imnovid®), Enasidenib (IDHIFA®), Sacituzumab Govitecan (Trodelvy®), Nab-paclitaxel (Abraxane®) and Luspatercept (Reblozyl®). Amongst others, he served as SVP Global Marketing & Strategy, VP Hematology Europe, Regional VP Middle & Eastern Europe and General Manager Germany for Celgene Corp., as well as in several German and European leadership roles in oncology and nephrology at AMGEN Inc.
Michael holds a Master of Science degree in Molecular Biology from Ludwig-Maximilians-University in Munich.